Peptide library / Digestive & weight / Dulaglutide
Dulaglutide
A once-weekly GLP-1 receptor agonist used in type 2 diabetes with proven heart benefit.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Lower blood sugar in type 2 diabetesFDA approved
- Fewer major heart events in type 2 diabetesLarge trials
How it is thought to work
Dulaglutide links a GLP-1 analog to part of an antibody, which extends its half-life and allows weekly dosing.
What the evidence shows
The REWIND trial enrolled a broad group of adults with type 2 diabetes, many without established heart disease, and found a reduction in major cardiovascular events compared with placebo.
Safety and unknowns
Gastrointestinal effects are common. The label carries the class boxed warning on thyroid C-cell tumors seen in rodents.
Regulatory status
FDA-approved as Trulicity in 2014. It is not approved specifically for weight management.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
Ecnoglutide
In clinical trialsAn investigational weekly GLP-1 receptor agonist developed in China by Sciwind Biosciences.
Efpeglenatide
In clinical trialsA long-acting GLP-1 receptor agonist that showed heart and kidney benefit in a large trial.
Cagrilintide
In clinical trialsAn investigational long-acting amylin analog from Novo Nordisk, tested alone and combined with semaglutide.
General information, not medical advice. Do not buy or inject unregulated peptides.